Evonile Pharma Limited (BOM:500672)

Evonile Pharma Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Operating Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	-39.9	931.8	1,009	851.9	1,034	-37.2
Depreciation & Amortization	52.1	19.5	21.9	26.1	60.6	96.5
Loss (Gain) From Sale of Assets	0.3	0.3	-1.1	-32.1	-28.9	1.4
Stock-Based Compensation	2.3	2.7	3.3	2.5	3.8	18.5
Provision & Write-off of Bad Debts	-0.7	-1.3	-1.7	1.7	3.7	-3.6
Other Operating Activities	-492	-346.6	-278.1	193.5	-384.8	-356.1
Change in Accounts Receivable	264.6	32.2	15	-53.4	80.3	-42
Change in Inventory	-1,189	-122.1	37.5	98.6	23.5	-91.2
Change in Accounts Payable	1,519	21.8	-92.5	21.2	-100.2	148.3
Change in Other Net Operating Assets	1,612	-71	32.4	24	-243.6	652.1
Operating Cash Flow	1,729	467.3	745.7	1,134	448	386.7
Operating Cash Flow Growth	298.57%	-37.33%	-34.24%	153.13%	15.85%	-

Investing Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-13,136	-3.4	-	-	-3.1	-5
Sale of Property, Plant & Equipment	0.2	0.2	3.2	32.7	39.4	-
Investment in Securities	5,301	-200.2	-449	-48.3	-1,769	720
Other Investing Activities	385.1	379.7	412.7	346.9	199.8	155.4
Investing Cash Flow	-7,450	176.3	-33.1	331.3	-1,533	870.4

Financing Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Long-Term Debt Repaid	-	-22	-24.1	-37	-57.4	-109
Lease Payments	-25.2	-22	-24.1	-37	-57.4	-109
Net Debt Issued (Repaid)	7,975	-22	-24.1	-37	-57.4	-109
Common Dividends Paid	-	-617.3	-617.3	-1,173	-246.9	-246.9
Other Financing Activities	-40.2	-	-0.1	-0.1	-0.5	-0.4
Financing Cash Flow	7,935	-639.3	-641.5	-1,210	-304.8	-356.3

Net Cash Flow

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Cash Flow	2,214	4.3	71.1	255.4	-1,389	900.8

Free Cash Flow

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	-11,406	463.9	745.7	1,134	444.9	381.7
Free Cash Flow Growth	-	-37.79%	-34.24%	154.89%	16.56%	-
Free Cash Flow Margin	-342.76%	13.09%	20.93%	33.84%	11.75%	9.55%
Free Cash Flow Per Share	-461.93	18.79	30.20	45.93	18.02	15.46
Levered Free Cash Flow	-8,069	612.49	484.19	498.14	568.16	1,205
Unlevered Free Cash Flow	-8,032	620.36	489	507.45	579.1	1,236
Free Cash Flow After Leases	-11,432	441.9	721.6	1,097	387.5	272.7

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	-	-	0.1	0.1	0.5	0.4
Cash Income Tax Paid	352.6	352.6	162.9	-382.7	-23.4	185.9
Change in Working Capital	2,207	-139.1	-7.6	90.4	-240	667.2

Data Source: S&P Global Market Intelligence Last updated: Nov 3, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 7, 2026

Data Sources Report a data error